NCT00605345View on ClinicalTrials.gov

A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Anemia

Interventions

DRUG

Darbepoetin alfa

As prescribed

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

120, 200 or 360 micrograms sc 4-weekly (starting dose)

Trial Locations (21)

13005

Ciudad Real

14004

Córdoba

15006

A Coruña

15706

Santiago de Compostela

18014

Granada

28007

Madrid

28040

Madrid

28041

Madrid

28222

Madrid

39008

Santander

46017

Valencia

47005

Valladolid

48903

Barakaldo

48960

Galdakao

03010

Alicante

06080

Badajoz

08915

Badalona

08003

Barcelona

08025

Barcelona

08036

Barcelona

08907

L'Hospitalet de Llobregat

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00605345 - A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients. | Biotech Hunter | Biotech Hunter